CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-11). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 253 · Search date 2026-07-11 · Methodology v0.6

Dihydromyricetin,
does it really help with Hangover prevention and relief?

30-Second Summary
?
Evidence Grade ? · Safety unknown
Unlike Hovenia extract, purified DHM alone has no human hangover efficacy literature available for grading
What the
research shows
No RCT of purified DHM alone for hangover was identified. Human monotherapy research on DHM does exist: Chen 2016 randomized 60 patients with NAFLD to purified DHM at 300 mg/day for three months, but that trial cannot be repurposed as evidence for hangover. Hovenia dulcis combinations, A. indica, and other ingredients are also not evidence for DHM alone, so the hangover claim remains rated ?.
What the
ads claim
Advertisements state that DHM rapidly clears acetaldehyde and prevents intoxication and hangover. Published human hangover evidence concerns Hovenia extracts or combinations, and the NAFLD monotherapy RCT cannot establish this hangover mechanism.
*

Useful facts when choosing a product

  • DHM is a flavonoid also known as ampelopsin.
  • The DHM content of Hovenia extracts can vary by raw material and standardization method.
  • Results from extract or combination-beverage trials are not the same as results for purified DHM alone.
  • An effective hangover dose and long-term safety range for DHM alone have not been established in published human trials.
Gap Measurement · Verdict 253 · ?
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The hangover-related clinical evidence in the Skinner 2026 systematic review consisted of a Hovenia dulcis extract trial in 26 healthy men and a combination-beverage trial in 25 adults; neither tested purified DHM alone for hangover. In contrast, Chen 2016 was a three-month RCT of purified DHM at 300 mg/day in 60 patients with NAFLD, confirming that human DHM monotherapy research exists, but it did not assess hangover and cannot be repurposed for that claim. Hovenia dulcis combinations and A. indica are separate ingredients.

02

Why this is classified as ?

A purified-DHM RCT exists in NAFLD, but there is no monotherapy efficacy trial for hangover. Under the boundary rule, another disease, extracts, combinations, and preclinical data are not transferred to the ingredient-specific hangover claim, so the rating is ? without a score.

Counterpoint. Small hangover signals from Hovenia fruit extract can support future DHM-only trials but do not evaluate the same target ingredient.

Rejudgment record. Reassessment (cross-check reflected) — A purified-DHM RCT exists in NAFLD, but there is no monotherapy RCT for hangover, and results from Hovenia dulcis combinations, A. indica, and other ingredients cannot be transferred to that claim

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Chen S et al. 2016Randomized controlled trial60UnknownMetabolic and liver-related outcomes in NAFLDPurified DHM at 300 mg/day was tested for three months, but the trial did not assess hangover.Scope-defining
Skinner SG et al. 2026Systematic review2UnknownPreclinical and clinical alcohol-related outcomesThe two hangover studies tested Hovenia dulcis extracts; no hangover trial of purified DHM alone was found.Key
Verster JC et al. 2021Market-product and evidence evaluation82UnknownIngredients, marketing claims, and independent safety and efficacy evidenceDHM was common, but independent human safety and efficacy evidence for product ingredients was not identified.Supportive
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-11).

Chen S, Zhao X, Wan J, et al. 2016. Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease. PMID: 26032587.
checked
Skinner SG, Matcha S, Davies DL. 2026. Therapeutic Effects of Dihydromyricetin on Wholly Alcohol-Attributed Conditions: A Systematic Review. Nutrients. 18(14):2221. DOI: 10.3390/nu18142221.
checked
Verster JC, van de Loo AJAE, Adams S, Stock AK, Benson S, Scholey A, Bruce G. 2021. Unknown safety and efficacy of alcohol hangover treatments puts consumers at risk. Addict Behav. 122:107029. PMID: 34225031. DOI: 10.1016/j.addbeh.2021.107029.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-11 · Corrections: none

Cite this verdict

Dihydromyricetin (DHM) x hangover prevention and relief Evidence Grade ? card
[Chamgap] Dihydromyricetin (DHM) x hangover prevention and relief — Evidence Grade ?. 3 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/liver/dihydromyricetin-hangover/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.